The Azd0466 AstraZeneca trial is expanding indications in phase 1 clinical trials globally as announced in February
AstraZeneca’s significantly expanded clinical program for AZD0466 will include a multi-centre global Phase 1 study in acute leukaemias.
This updated program will expedite development of AZD0466 with the objective of obtaining regulatory approval for specific indications of high unmet clinical need and this represents AstraZeneca's major focus.
- Forums
- ASX - By Stock
- SPL
- Astra Zeneca Quarterly
Astra Zeneca Quarterly, page-16
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.4¢ |
Change
0.001(1.08%) |
Mkt cap ! $38.73M |
Open | High | Low | Value | Volume |
9.4¢ | 9.6¢ | 9.2¢ | $11.66K | 123.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 28393 | 9.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.6¢ | 2593 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 28393 | 0.093 |
1 | 247718 | 0.092 |
1 | 48440 | 0.091 |
2 | 80000 | 0.090 |
1 | 400000 | 0.089 |
Price($) | Vol. | No. |
---|---|---|
0.096 | 2593 | 1 |
0.098 | 19848 | 1 |
0.099 | 630 | 1 |
0.100 | 52000 | 2 |
0.105 | 92396 | 2 |
Last trade - 14.37pm 03/07/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online